Company Description
Merck & Co., Inc. operates as a healthcare company worldwide.
The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
The company has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors.
Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Country | United States |
| Founded | 2000 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,000 |
| CEO | Robert Davis |
Contact Details
Address: 126 East Lincoln Avenue Rahway, New Jersey 07065 United States | |
| Phone | 908 740 4000 |
| Website | merck.com |
Stock Details
| Ticker Symbol | MRK |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000310158 |
| CUSIP Number | 58933Y105 |
| ISIN Number | US58933Y1055 |
| Employer ID | 22-1918501 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert M. Davis J.D. | Chairman, President and Chief Executive Officer |
| Caroline A. Litchfield | Executive Vice President and Chief Financial Officer |
| Betty D. Larson | Executive Vice President and Chief Human Resources Officer |
| Richard R. DeLuca Jr. | Executive Vice President and President of Merck Animal Health |
| Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President and President of Merck Research Laboratories |
| Dalton E. Smart III | Senior Vice President of Finance, Principal Accounting Officer and Global Controller |
| David Michael Williams | Executive Vice President and Chief Information and Digital Officer |
| Peter Dannenbaum | Vice President of Investor Relations |
| Jennifer L. Zachary J.D. | Executive Vice President and General Counsel |
| Cristal N. Downing | Executive Vice President and Chief Communications and Public Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 3, 2025 | 144 | Filing |
| Oct 30, 2025 | 8-K | Current Report |
| Sep 9, 2025 | 8-K | Current Report |
| Sep 4, 2025 | 424B5 | Filing |
| Sep 3, 2025 | FWP | Free Writing Prospectus |
| Sep 2, 2025 | 424B5 | Filing |
| Aug 13, 2025 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Jul 29, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |